-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

Benzinga·08/19/2026 13:46:49
Listen to the news
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $56 to $48.